Chronic gouty arthritis and kidney damage: a clinical example

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Gout is a pathological condition characterized by hyperproduction of uric acid due to increased synthesis of endogenous purines or impaired excretion of uric acid by the kidneys. Despite the popularity of the main classical clinical manifestations of gout, such as tofuses, increased uric acid levels and arthritis, its diagnosis still causes great difficulties. At the same time, gout is closely associated with impaired kidney function, which makes diagnosis difficult. In this article, using a clinical example, we consider typical cases that arise during the diagnosis of this pathology.

Full Text

Restricted Access

About the authors

V. V. Poliakova

I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: scvssd@yandex.ru

Candidate of Medical Sciences, Associate Professor

Russian Federation, Saint Petersburg

N. A. Kunitskaya

I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia

Email: scvssd@yandex.ru

Doctor of Medical Sciences, Professor

Russian Federation, Saint Petersburg

References

  1. Cheng Shi, Ziting Zhou, Xiaowei et al. Recent advances in gout drugs. Eur J Med Chem. 2023; 245 (Pt 1): 114890. doi: 10.1016/j.ejmech.2022.114890
  2. Qaseem A., McLean R.M., Starkey M. et al. Diagnosis of acute gout: a clinical practice guideline from the American College of physicians. Ann Intern Med. 2017; 166 (1): 52–7. doi: 10.7326/M16-0569
  3. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76 (1): 29–42. doi: 10.1136/annrheumdis-2016-20970
  4. Chenjing Wang, Qing Yu, Xin Jiang et al. A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. J Clin Pharmacol. 2023; 63 (2): 239–49. doi: 10.1002/jcph.2159
  5. Mitsuboshi S., Kotake K. Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2023; 89 (3): 956–66. doi: 10.1111/bcp.15655
  6. Te Kampe R., Boonen A., Jansen T. et al. Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients. RMD Open. 2022; 8 (1): e001979. doi: 10.1136/rmdopen-2021-001979

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Patient A.: multiple large tophuses in the hands of both hands (a), elbow joints (б), feet (в), knee joints (г)

Download (301KB)
3. Fig. 2. X-ray of the joints of the hands (a) and feet (б) of patient A. with characteristic changes for gout

Download (208KB)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies